929905-12-4
Chemical Structure
PAMP-12 (unmodified)
- CAS No.: 929905-12-4
- Formula:C77H118N24O15
- Molecular Weight:1619.91
IUPAC Name: 2-(10-phenylanthracen-9-yl)-2,3-dihydro-1H-naphtho[1,8-de][1,3,2]diazaborinine
SMILES: N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O)CC4=CNC5=CC=CC=C45)=O)=O)=O)=O
Biological Activity: PAMP-12 (unmodified) is an endogenous peptide and is a MrgX2 agonist. PAMP-12 (unmodified) can reduce cAMP accumulation, increase Ca2+ levels, enhance beta-arrestin recruitment, decrease IP-1, and increases phosphoERK. PAMP-12 (unmodified) can elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells. PAMP-12 (unmodified) can be used for the research of hypotension and ulcerative colitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PAMP-12 (unmodified) | 99.40% | PAMP-12 (unmodified) is an endogenous peptide and is a MrgX2 agonist. PAMP-12 (unmodified) can reduce cAMP accumulation, increase Ca2+ levels, enhance beta-arrestin recruitment, decrease IP-1, and increases phosphoERK. PAMP-12 (unmodified) can elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells. PAMP-12 (unmodified) can be used for the research of hypotension and ulcerative colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kamohara M, et al. Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides[J]. Biochemical and biophysical research communications, 2005, 330(4): 1146-1152.
- [2]. Chen E, et al. Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target. Gastroenterology. 2021;160(5):1709-1724. [Content Brief]
